The Association of Anticholinergic Drugs and Delirium in Nursing Home Patients With Dementia: Results From the SHELTER Study
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
PubMed
34197793
DOI
10.1016/j.jamda.2021.05.039
PII: S1525-8610(21)00558-2
Knihovny.cz E-zdroje
- Klíčová slova
- Delirium, anticholinergic medications, dementia, nursing home patients,
- MeSH
- cholinergní antagonisté škodlivé účinky MeSH
- delirium * chemicky indukované epidemiologie MeSH
- demence * farmakoterapie epidemiologie MeSH
- hospitalizace MeSH
- léčivé přípravky * MeSH
- lidé MeSH
- pečovatelské domovy MeSH
- průřezové studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Názvy látek
- cholinergní antagonisté MeSH
- léčivé přípravky * MeSH
OBJECTIVES: Drugs with anticholinergic properties are associated with an increased prevalence of delirium, especially in older persons. The aim of this study was to evaluate the association between the use of this class of drugs in nursing home (NH) patients and prevalence of delirium, particularly in people with dementia. DESIGN: Cross-sectional multicenter study. SETTING AND PARTICIPANTS: 3924 nursing home patients of 57 nursing homes in 7 European countries participating in the Services and Health for Elderly in Long TERmcare (SHELTER) project. METHODS: Descriptive statistics, calculation of percentage, and multivariable logistic analysis were applied to describe the relationship between anticholinergic drug use and prevalence of delirium in NH patients. The Anticholinergic Risk Scale (ARS) and the Anticholinergic Burden Scale (ACB) were used to calculate the anticholinergic load. RESULTS: 54% of patients with dementia and 60% without dementia received at least 1 anticholinergic drug according to the ACB. The prevalence of delirium was higher in the dementia group (21%) compared with the nondementia group (11%). Overall, anticholinergic burden according to the ACB and ARS was associated with delirium both in patients with and without dementia, with odds ratios ranging from 1.07 [95% confidence interval (CI) 0.94-1.21] to 1.26 (95% CI 1.11-1.44). These associations reached statistical significance only in the group of patients with dementia. Among patients with dementia, delirium prevalence increased only modestly with increasing anticholinergic burden according to the ACB, from 20% (with none or minimal anticholinergic burden) to 25% (with moderate burden) and 27% delirium (with strong burden scores). CONCLUSIONS AND IMPLICATIONS: The ACB scale is relatively capable to detect anticholinergic side effects, which are positively associated with prevalence of delirium in NH patients. Given the modest nature of this association, strong recommendations are currently not warranted, and more longitudinal studies are needed.
Agaplesion Bethesda Clinic Geriatric Centre Ulm Alb Donau Ulm University Ulm Germany
Department of Neurology Amsterdam UMC University of Amsterdam Amsterdam the Netherlands
Department of Welfare National Institute for Health and Welfare Helsinki Finland
Department on Aging Netherlands Institute of Mental Health and Addiction Utrecht the Netherlands
Psychogeriatric Observation Unit Institution for Mental Health Care Parnassia Groep the Netherlands
Research Unit Health Environment Ageing Versailles Saint Quentin en Yvelines University Paris France
Citace poskytuje Crossref.org